Steroid-Sparing Plan with Olanzapine and Palonosetron to Prevent Nausea in High-Dose Cisplatin

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a dexamethasone-sparing approach for preventing nausea and vomiting in cancer patients receiving high-dose cisplatin. Olanzapine and palonosetron are used as the antiemetic backbone, with cisplatin as the emetogenic driver. Eligible participants have a histologically confirmed solid tumor and are starting their first cisplatin cycle at 50 mg/m2 or higher. The trial aims to determine whether this regimen can provide effective control of emesis while reducing steroid exposure. Safety and tolerability will be monitored, including potential allergic reactions and liver or kidney function concerns.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically confirmed solid malignancy
* scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2

Exclusion Criteria:

* pregnancy
* pelvic or abdominal radiation within 4 weeks
* uncontrolled brain metastasis
* other moderate or high emetic risk chemotherapy on day 2-5
* untreated gut obstruction
* known allergy or severe adverse effect from palonosetron or olanzapine
* AST/ ALT \> 2.5x or serum creatinine clearance less than 50 ml/min

Where it's running

• Faculty of Medicine Siriraj Hospital, Mahidol University
  Bangkok, Thailand Recruiting

Study contacts

• Study coordinator: Suthinee Ithimakin
• Email: aesi105@yahoo.co.th
• Phone: +66898127440

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• Olanzapine-based, dexamethasone-sparing antiemetic regimen for breast cancer patients with metabolic risk factors

  This study tests whether an olanzapine-containing antiemetic plan can match the usual dexamethasone-containing approach in preventing delayed chemotherapy-induced nausea and vomiting for breast cancer patients with metabolic risk factors.

  Recruiting Alexandria University · Alexandria, Alexandria Governorate · NCT07743827

• Dietary Supplements and Cancer Patients: Use, Tolerance, and Interactions

  This study looks at how many cancer patients take dietary supplements, how they tolerate them, and whether these supplements interact with cancer treatments.

  Recruiting Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) · Rabat · NCT07670234

• SBRT-LATTICE-PATHY for Large Tumors

  This trial tests a targeted radiotherapy approach (SBRT-LATTICE-PATHY) to treat large, intractable solid tumors in adults.

  Recruiting Phase 2 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07645261

• Balanced IV Fluids for Kids with Acute Gastroenteritis

  This study compares balanced crystalloids versus normal saline for IV hydration in young children with acute gastroenteritis to see if it improves acid–base status and clinical outcomes.

  Recruiting Aydin Adnan Menderes University · Aydin · NCT07610382

• Does the 1939 Cancer Act still work in the internet and social media age?

  This survey asks people treated for cancer and health professionals in England and Wales about online and social media cancer information to see if the 1939 Cancer Act needs updating.

  Recruiting Royal Cornwall Hospitals Trust · Truro · NCT07584824

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.